Comparative Pharmacology
Head-to-head clinical analysis: BUTORPHANOL TARTRATE versus ROXILOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTORPHANOL TARTRATE versus ROXILOX.
BUTORPHANOL TARTRATE vs ROXILOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.5 hours (mean ~3 hours) in adults; prolonged in hepatic impairment (up to 5-6 hours) and renal impairment (variable, may increase).
Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for approximately 70-80% of elimination (mostly metabolites), with 15-20% via feces (biliary). Less than 5% excreted unchanged in urine.
Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized
Category C
Category C
Opioid Analgesic
Opioid Analgesic